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428Introduction: Unambiguous data on sexual dysfunction after Hodgkin lymphoma (HL) treatment are scarce.
Aims: To form a baseline in this area, we compared patient-reported sexual function in sexually active male HL
survivors in complete remission with a sexually active, age-matched, male Dutch sample population. Further-
more, we explored whether sociodemographic and clinical factors were associated with sexual dysfunction in HL
survivors and investigated whether reporting to perceive sexual problems was indicative for sexual dysfunction.
Methods: This cross-sectional study included male patients with HL who were treated with chemotherapy and
age-matched sexually active males.
Main outcome measures: Outcome measures included the internationally validated International Index of
Erectile Function (IIEF) and self-reported sexual problems by adding 3 items to the study-specific questionnaire.
Results: Erectile dysfunction (ED) occurred in 23.3% of the HL survivors vs in 23.0% of controls: respectively
13.3% and 12.3% had moderate to severe ED. However, more HL survivors positively answered the question
whether they did perceive sexual problems than controls (20.0% vs 7.0%; P ¼ .087). More patients treated with
bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procabazine, and prednisone (BEACOPP) had
sexual problems 33.3% vs 8.3% who were treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
(P ¼ .057). Importantly, we found that the mean IIEF score for erectile function was 15.7 in HL survivors who
reported to perceive sexual problems (moderate ED) vs 28.3 (normal) in those without perceiving sexual problems.
Conclusion: In general, sexual function of male HL survivors is comparable to that of matched normal controls.
Perceiving sexual problems was associated with lower sexual function measured by the IIEF. None of the HL
survivors who were treated with doxorubicin, bleomycin, vinblastine, and dacarbazine perceived sexual problems.
However, one-third of HL survivors who were treated with BEACOPP did, including ED in one-third of the
cases. This is an important consideration for daily clinical practice as BEACOPP is increasingly used as standard
therapy in advanced-stage HL. Eeltink CM, Lissenberg-Witte BI, Incrocci L, et al. Self-Reported Sexual
Function in Sexually Active Male Hodgkin Lymphoma Survivors. Sex Med 2020;8:428e435.
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During the past few decades, more effective therapy has led to
better survival rates among patients with Hodgkin lymphoma
(HL), and cures can presently be as high as 80e90%.1,2
Nevertheless, treatment-related toxicity is still a major concern,
and while long-term follow-up has revealed much detailed in-
formation, unambiguous data on sexual dysfunction after HL
treatment are scarce.
Overall, sexual dysfunctionmay consist of a loss of sexual desire,
arousal, difficulties reaching orgasm, pain with erection or orgasm,
sexual satisfaction, or discontinuation of sexual activity.3e11
Among men treated for cancer, the most common sexual prob-
lems are a loss of sexual desire and erectile problems.12 Sexual
dysfunction can have a variety of causes such as testicular damage,
especially due to alkylating treatment agents and radiotherapy.13,14
As a result, subnormal testosterone levels (hypogonadism) may
lead to problems with sexual function.5e11 In addition, cancer and
its treatment can have negative effects on physiological, as well as
psychological and interpersonal factors, which subsequently may
impact on sexual function and satisfaction.3e5,7,9e11
The fact that sexual dysfunction can be a problem in HL has
been shown in a series of reports with 24 male HL survivors by
Hannah et al, (1992)15 to 1,826 male HL survivors by Behringer
et al (2013).16 Even so, the exact extent of the problem is un-
known, and reported results vary widely from 20% to 63%.16e23
In addition, there are heterogeneous reports on these effects
which compare patients to the general population, again with a
large variation in results.16,22
A problem with any new avenue of retrospective research is the
lack of stable reporting scenarios against which comparisons can be
made. To start with, the aforementioned variationmight simply be
explained by differences in the definitions of sexual dysfunctions.
These are often subjective ranging from reporting “decreased
sexual enjoyment” to actual “erectile dysfunction.” In addition,
various (non)standardized and (non)validated questionnaires have
been used,3 and when comparing new findings, only a limited
number of prior studies took the sexual dysfunction rate in the
general male population into consideration.8,16,22,23 Critically,
none of these studies used the International Index of Erectile
Function (IIEF)24,25 questionnaire which has presently been
adopted as the “gold standard” for efficacy assessment in clinical
trials investigating erectile dysfunction and when measuring male
sexual function in male cancer populations.4 In the largest series
describing the outcome of 1,826 male HL survivors reported by
the German Hodgkin Study Group, the European Organisation
for Research and Treatment of Cancer-sexual function scale was
used, based on 3 questions, and being validated in patients with
testicular cancer only.16
There is little doubt that as patients live longer, sexual issues
will become more important. To help form a base line for this
research area, we compared self-reported sexual function in
sexually active male HL survivors with that of a sample drawnSex Med 2020;8:428e435from sexually active, age-matched, Dutch males. We used the
standardized and validated IIEF questionnaire. To support early
detection of sexual dysfunction in HL survivors in the future, we
also investigated whether sociodemographic factors and treat-
ment regimen were associated with sexual dysfunction. Finally,
we investigated whether reporting to perceive sexual problems
was indicative for sexual dysfunction.MATERIALS AND METHODS
Study Design and Participants
This cross-sectional survey study was conducted in the VU
University Medical Center in 2008. From a cohort of 112 HL
survivors, patients who were treated between September 2002 and
December 2007 were identified. The recruitment of the sample is
presented in Figure 1. Patients whowere treatedwith either ABVD
regimen—doxorubicin, bleomycin, vinblastine, and dacarbazine
(baseline and/or escalated)—or BEACOPP regimen—bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine, procaba-
zine, and prednisone, with or without adjuvant involved
field—were also identified. Patients had to be in complete remis-
sion at the time of the study. Patients with severe physical ormental
comorbidity, or who were not sexually active at the moment of the
questionnaire, were excluded. Eligible patients were contacted and
informed by telephone. After showing an interest to participate,
the patient information letter, informed consent form, and ques-
tionnaire were sent by regular mail.Control Population
In 2014, adult male members of a Dutch internet panel
(www.panelclix.nl), representative of the general Dutch popula-
tion, were asked if they might participate in a digital survey on
sexual function for which a fee of 5 Euro per person was paid.
Panelclix is an International Organization for Standardization
(ISO)-certified European online recruitment agency. An online
studyespecific questionnaire was developed whereby informa-
tion on age, marital status, and sexual activity was obtained. In
addition, the IIEF questionnaire (discussed in the following
sections) was used.
A total of 205 male participants completed the survey from
which sexually inactivemales were excluded (n¼ 13). This resulted
in a database of 192 sexually active males. Each HL survivor
(n¼ 30) was age-matched with 2 controls, randomly selected from
the control population. 3 HL survivors could only be matched to
one control, which resulted in a total of n ¼ 57 controls.Procedure
Sexual Function
Sexual function was evaluated by means of the IIEF. The IIEF
is a validated, 15-item self-report questionnaire for the evaluation
of male sexual function.25 The IIEF comprises 5 subscales,
including erectile function, orgasmic function, sexual desire,
Figure 1. Flow of patients.
430 Eeltink et alintercourse satisfaction, and overall satisfaction. For grading
erectile dysfunction, the cutoff scores as defined by Cappelleri
et al24 have been used. For all other domains, no standard
reference cutoffs have been identified; a higher score indicates
better sexual function.24,25
Sexual Problems
In addition, perceived sexual problems were evaluated in the
study-specific questionnaire by adding 3 items to it: (i) Do you
perceive a sexual problem? (ii) If yes, please define the prob-
lem(s); (iii) Did the problem(s) improve, remain unchanged,
resolve, or worsen since the treatment for HL began?Sociodemographic and Clinical Characteristics
In addition, items on sociodemographic variables (age, committed
relationship) were assessed in the study-specific questionnaire.
Disease-specific items (date of HL diagnosis, stage of disease, treat-
ment, time since treatment) were derived from medical records.
Time in remission was calculated from date of complete remission
until the date of questionnaire. Follow-up time (in months) was
calculated from diagnosis until the date of questionnaire.Ethical Consideration
The study was approved by the Ethics Committee of the VU
University Medical Center, Amsterdam, the Netherlands. The
study was conducted according to the Declaration of Helsinki,
International Conference on Harmonisation Good Clinical
Practice Guidelines, and the EU directive for Good Clinical
Practice (2001/20/EG).Data Analysis
All statistical analyses were performed using SPSS version 22
(IBM Corp, Armonk, NY). Dichotomous variables are described
by frequency and percentage. All subscales and the total score of the
IIEF are described by mean and standard deviation, and all other
continuous normally distributed variables by mean and standard
deviation and continuous nonnormally distributed variables by
median and range. Reporting the presence of a sexual problem and
erectile dysfunction according to the IIEF and the scores of the
subscales and total score of IIEF were compared between the HL
survivors and the controls using the Fisher's exact test for dichot-
omous outcomes and the Mann-Whitney U test for continuous
subscales. Relations between clinical or sociodemographical factors
and sexual function in HL survivors were assessed via the Fisher's
exact test (for dichotomous factors), independent samples t-test
(for the continuous factor age), and Mann-Whitney test (for the
IIEF subscales and other nonnormal continuous factors). P values
< .05 were considered to be significant.RESULTS
Patient Sociodemographic and Clinical
Characteristics
In total, 30 HL survivors were analyzed. Sociodemographic and
clinical characteristics of male HL survivors are presented in
Table 1. The median age of the HL survivors was 38 years (range:
22e63), and 90% were in a committed relationship. All survivors
(n ¼ 30) had been treated with combination chemotherapy, 12
survivors had been treated with 2e4 cycles ABVD, and 17 survi-
vors with 4e8 cycles standard or dose-escalated BEACOPP. OneSex Med 2020;8:428e435
Table 1. Demographic characteristics of HL survivors
Sample characteristics
N ¼ 30
N %
Age at diagnosis (years)
Mean (SD) 36 (10)
Age at time of study (years)
Mean (SD) 39 (10)
Time in remission (months)
Median (range) 38 (9e83)
Follow-up time (months)
Median (range) 47 (14e89)
Relationship status
Committed relationship 27 90.0
No committed relationship 3 10.0
Stage of disease
I þ II 18 60.0
III þ IV 12 40.0
BEACOPP regimen (%) 18 (60.0)
8 Cycles BEACOPP escalated 8 44.4
8 Cycles BEACOPP 2 11.1
6 Cycles BEACOPP escalated 4 22.2
4 Cycles BEACOPP escalated þ 4
cycles BEACOPP
3 16.7
2 Cycles BEACOPP escalated þ 2
cycles ABVD
1 5.6
ABVD regimen 12 (40.0)
4 cycles ABVD 7 58.3
2e4 cycles ABVD like 5 41.7
Involved field radiotherapy
No 15 (50.0)
BEACOPP regimen 15 100.0
ABVD regimen 0 0.0
Yes 15 (50.0)
BEACOPP regimen 3 20.0
ABVD regimen 12 80.0
ABVD ¼ doxorubicin, bleomycin, vinblastin, and dacarbazin; BEACOPP ¼
bleomycin, etoposide, doxorubicin, cyclophosphamide, oncovin, procabazine,
and prednisone; HL ¼ Hodgkin lymphoma; SD ¼ standard deviation.
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andABVD. Adjuvant radiotherapy (involved field) was given to 15
patients, of whom 3 were treated with BEACOPP regimen. All 15
patients who did not receive radiotherapy received a BEACOPP
regimen. 2 patients underwent pelvic irradiation, one in combi-
nation with ABVD and one in combination with BEACOPP. 2
patients had received autologous stem cell transplantation because
of recurrent disease, both patients had a stage II disease, one
received ABVD in combination with adjuvant radiotherapy, and
the other patient received 8 cycles of BEACOPP in combination
with adjuvant radiotherapy.
The median time of remission was 38 months (range:
9e83 months). The median follow-up time since treatment was
47 months (range: 14e89 months). In the medical records, no
notes on provided sexual support were found.Sex Med 2020;8:428e435Differences in Sexual Functioning
The IIEF questionnaire revealed no differences in sexual func-
tion between HL survivors and controls (Table 2). Also the degree
of erectile dysfunction was comparable between HL survivors and
controls: 23.3% of HL survivors reported mild to severe erectile
dysfunction and 23.0% in controls (odds ratio 1.03) (Table 2).Differences in Sexual Problems
HL survivors perceived more sexual problems than controls,
although this was not statistically significant (20.0% vs 7.0%;
P¼ .087) (Table 2). The following problems were reported byHL
survivors: lack of sexual desire (n ¼ 3), problems with getting
aroused (n ¼ 2), no firm erection (n ¼ 2), problem getting too
aroused (n¼ 1), erection not possible (n¼ 1), self perceived sexual
unattractiveness (n ¼ 1), and lack of condition (n ¼ 1). Sexual
problems were not present before the start of therapy but devel-
oped during or after treatment. None of the problems disappeared.Differences in Sociodemographic and Clinical
Characteristics
Table 3 presents the associations of sociodemographic and
clinical factors with sexual function in HL survivors. Differ-
ences were observed between survivors treated by BEACOPP
and those treated by ABVD, although these were not statis-
tically significant. Overall satisfaction was found to be lower
in survivors treated with BEACOPP (mean 7.8 ± 2.7 vs
9.5 ± 0.8 survivors treated with ABVD, P ¼ .065).
Accordingly, more HL survivors who were treated with a
BEACOPP regimen perceived sexual problems than those
who were treated with ABVD (6/18 [33.3%] vs 0/12 [0.0%],
P ¼ .057).Association Between Sexual Functioning According
to IIEF vs Perceiving a Sexual Problem
Finally, we investigated whether reporting perceived sexual
problems was indicative for sexual dysfunction as measured by the
IIEF. All domains of the IIEF were found to be associated with
perceiving sexual problems, except for orgasmic function
(Table 4). In patients perceiving sexual problems, IIEF scores were
lower, indicating less sexual function. In addition, in patients
perceiving sexual problems, the mean IIEF score for erectile
function was 15.7, indicative for moderate erectile dysfunction,
whereas in patients without perceiving sexual problems, the mean
IIEF score for erectile dysfunction was 28.3 being normal.DISCUSSION
This retrospective study was performed to form a baseline for
research into sexual functioning among male HL survivors. Pa-
tients were compared to an age-matched male control population
(Table 1) and, on average, had been treated with standard
treatment regimens 4 years previous to this investigation. To the
Table 2. Comparison of main outcome measures of HL survivors and age-matched controls
Main outcome measures Score range
HL survivors Age-matched controls
N ¼ 30 N ¼ 57 P value
IIEF subscales Mean SD Mean SD
Erectile function 1e30 25.8 7.3 26.1 6.1 .60
Orgasmic function 0e10 9.2 2.0 9.4 2.0 .42
Sexual desire 2e10 7.2 1.9 7.7 1.6 .24
Intercourse satisfaction 0e15 10.2 4.2 10.3 4.4 .73
Overall satisfaction 2e10 8.5 2.3 7.9 2.3 .11
IIEF total 5e75 60.8 15.1 61.3 12.8 .87
Erectile function score N % N %
No erectile dysfunction 26e30 23 76.7 44 77.0 .68
Mild erectile dysfunction 22e25 1 3.3 2 3.5
Mild to moderate erectile dysfunction 17e21 2 6.7 4 7.0
Moderate erectile dysfunction 11e16 1 3.3 5 8.8
Severe erectile dysfunction 1e10 3 10.0 2 3.5
Perceiving a sexual problem .087
Yes 6 20.0 4 7.0
No 24 80.0 53 93.0
HL ¼ Hodgkin lymphoma; IIEF ¼ International Index of Erectile Function; SD ¼ standard deviation.
432 Eeltink et albest of our knowledge, this is the first study to compare the IEFF
scores with an age-matched male control population.
In general, sexual function ofmaleHL survivors was found to be
comparable to that of matched normal controls, with respect to all
IIEF subscales comprising function, desire, and satisfaction.
Furthermore, the degree of ED was comparable between HL
survivors and controls: 23.3% in HL survivors and 23.0% in
control—respectively 13.3% and 12.3% had moderate to severe
erectile dysfunction. This has been reported previously and in-
dicates that no additional care is needed in male HL survivors.16,22
However, the prevalence of sexual problems in our population
of HL survivors was remarkably lower than that recorded in
another which used the validated Global Sexual Satisfaction Index
from the Derogatis Sexual Functioning Inventory.22 In this latter
study, 54% of HL survivors (>7 years after treatment) reported
decreased sexual activity, and 41% reported a decreased interest in
sex. This may be due to the fact that our sample included a het-
erogeneously treated population, with 40% of early stage patients
treated with ABVD and 60% of higher risk patients treated with
BEACOPP. We found that although none of the HL survivors
whowere treated with ABVDperceived sexual problems, 33.3%of
HL survivors who were treated with BEACOPP did. Behringer
et al16 reported that only survivors with early stages of HL reached
the same levels of sexual functioning after therapy compared with
controls, while survivors with higher stages of HL were more likely
to develop long-term sexual problems. This is probably explained
by the fact that the BEACOPP schedule includes 2 alkylating
agents, namely procarbazine and cyclophosphamide, while the
ABVD regimen has only one, namely dacarbazine.
Alkylating agents can lead to damage of the gonads, a well-
known cause of sexual dysfunction.6e11,13,14,16 Apart fromthese drugs, gonadal effects also depend on cumulative doses and
combinations that have been applied.26 Given the type of sexual
problems reported by HL survivors who received the BEACOPP
regimen, in particular, the lack of desire and problems with
arousal, hypogonadism probably plays a role.
Furthermore, we found that patients perceiving themselves the
presence of sexual problems were associated with them having a
lower sexual function measured by the IIEF. This is in line with
our previous study on the sexual functioning of young female HL
survivors.27
It appears that sexual dysfunction can easily be detected by
early screening of sexual problems using just 3 questions. This
would allow early specific intervention in the affected domain, as
intervention strategies have been shown to minimize sexual
dysfunction.5,28 We recommend monitoring these patients for
perceiving a sexual problem, to prevent clinical symptoms.29
There are some limitations with the study to be acknowl-
edged. First, many HL survivors have been excluded because of
severe physical or mental comorbidity. In retrospect, it would
have been better to have informed all patients instead of
excluding on own interpretation. Second, our study design does
not allow conclusions to be drawn on the evolution of sexual
dysfunction over time, especially as early-onset sexual problems
may be overlooked because of the 4-year median time between
diagnosis and treatment. Moreover, it is possible that the pre-
vious treatment is not the sole influencer of the sexual
dysfunction. Nevertheless, we feel the strength of our study is the
identification and reporting of persistent sexual problems, which
can now be addressed; after all, it has been previously reported
that an improvement in sexual function is not to be expected for
2 years after hematopoietic stem cell transplantation.30 As lateSex Med 2020;8:428e435
Table 3. Associations of sociodemographic and clinical factors with sexual function in HL survivors
Variable
International Index of Erectile Function Erectile dysfunction Perceiving a sexual problem
Erectile function
Orgasmic
function Sexual desire
Intercourse
satisfaction
Overall
satisfaction Total score IIEF Yes No Yes No
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD N (%) N (%) N (%) N (%)
Relationship
status
Committed
relationship
26.3 ± 6.6 9.6 ± 0.9 7.4 ± 1.8 10.6 ± 3.9 8.7 ± 2.0 62.6 ± 12.5 6 (22.2) 21 (77.8) 5 (18.5) 22 (81.5)
No committed
relationship
21.0 ± 13.0 5.7 ± 5.1 5.3 ± 2.1 6.7 ± 5.9 6.0 ± 3.5 44.7 ± 29.4 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7)
Stage of disease
IeII 27.4 ± 5.2 9.4 ± 1.1 7.1 ± 1.7 10.8 ± 3.3 9.1 ± 1.5 63.8 ± 10.5 3 (16.7) 15 (83.3) 3 (14.3) 15 (85.7)
IIIeIV 23.3 ± 9.4 8.8 ± 2.9 7.3 ± 2.1 9.3 ± 5.3 7.6 ± 2.9 56.4 ± 20.0 4 (33.3) 8 (66.7) 3 (25.0) 9 (75.0)
Chemotherapy
ABVD regimen 28.3 ± 2.6 9.2 ± 1.3 7.7 ± 1.5 11.5 ± 2.1 9.5 ± 0.8* 66.2 ± 5.6 1 (8.3) 11 (91.7) 0 (0.0)† 12 (100.0)
BEACOPP
regimen
24.1 ± 8.9 9.2 ± 2.4 6.8 ± 2.0 9.4 ± 5.0 7.8 ± 2.7 57.3 ± 18.4 6 (33.3) 12 (66.7) 6 (33.3) 12 (66.7)
Involved field
radiotherapy
No 24.3 ± 8.7 9.1 ± 2.6 6.9 ± 2.0 9.6 ± 4.8 7.8 ± 2.7 57.7 ± 17.9 5 (33.3) 10 (66.7) 4 (26.7) 11 (73.3)
Yes 27.3 ± 5.6 9.3 ± 1.2 7.4 ± 1.7 10.9 ± 3.6 9.1 ± 1.6 64.0 ± 11.5 2 (13.3) 13 (86.7) 2 (13.3) 13 (86.7)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age at time of
study (years)
44.4 ± 13.8 38.0 ± 9.0 46 ± 13 38 ± 9
Median (range) Median
(range)
Median
(range)
Median (range)
Time since start
treatment
(months)
29 (18e74) 48 (14e89) 51 (29e74) 46 (14e89)
Time since
remission
(months)
22 (9e60) 44 (9e83) 31 (22e60) 41(9e83)
ABVD ¼ adriamycin, bleomycin, vinblastin, and dacarbazin; BEACOPP ¼ bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procabazine, and prednisone; HL ¼ Hodgkin lymphoma;
IIEF ¼ International Index of Erectile Function; SD ¼ standard deviation.
*P ¼ .065.
†P ¼ .057.
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Table 4. Comparison of main outcome measure between HL survivors with vs without a sexual problem
HL survivors with a
sexual problem
HL survivors without
a sexual problem
IIEF subscales Score range N ¼ 6 N ¼ 24
P valueMean SD Mean SD
Erectile function* 1e30 15.7 10.2 28.3 3.5 .005*
Orgasmic function 0e10 7.7 3.9 9.6 0.97 .21
Sexual desire 2e10 5.7 2.2 7.5 1.6 .05*
Intercourse satisfaction 0e15 5.5 5.0 11.4 3.1 .005*
Overall satisfaction 2e10 5.5 3.2 9.2 1.2 .003*
IIEF total 5e75 40.0 20.9 66.0 7.3 .001*
HL ¼ Hodgkin lymphoma; IIEF ¼ International Index of Erectile Function; SD ¼ standard deviation.
*P < .05.
434 Eeltink et aleffects on gonadal function due to alkylating agents are present
both after transplantation and after treatment for HL lymphoma,
a similar pattern is to be expected in this patient population.
Another possible criticism is that the control population con-
sisted of paid members of an online panel, so bias might have
been induced. However, we expect that men with sexual
dysfunction are more willing to participate in a survey as opposed
to men without problems, overrating the incidence in the normal
population. In addition, we could only match for age, as other
factors such as comorbidities, which affect sexual function, could
not be corrected for. However, as our survivor population is
young with a median age of 38, we suppose such influence is
limited. Finally, owing to its introductory nature, this study
concerns a relatively small number of participants. Even so, we
found a (near) statistical significance. In our opinion, this work
creates a baseline for further research and monitoring as we
believe that increasing the number of patients will only
strengthen our conclusions.CONCLUSIONS
We found that sexual function of male HL survivors, as
measured by the IIEF, is comparable to that of matched normal
controls. However, the type of treatment seems important; while
none of the HL survivors who were treated with ABVD perceived
sexual problems, one-third of HL survivors who were treated with
BEACOPP did, including erectile dysfunction in one-third of
cases. Eliciting perceived sexual problems revealed by using just 3
questions was associated with lower sexual function measured by
the IIEF. The use of screening for perceiving sexual problems
using a simple tool to identify patients who might have sexual
dysfunction should be further explored. The IIEF questionnaire
to identify and quantify the nature and extent of sexual problems
should be used in cases where patients report issues, permitting
early intervention in affected domains and potentially improving
quality of life. This is an important consideration for daily clinical
practice as BEACOPP is increasingly used as standard therapy in
advanced-stage HL.ACKNOWLEDGMENTS
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